Shareholders meeting

July 09, 2026 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543904 Symbol: MANKIND Dear Sir/ Madam, Subject: Notice of Thirty-Fifth Annual General Meeting (“35th AGM”) and Annual Report for the financial year 2025-26 Ref: Regulation 30, 34(1), 50(2), 53(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) In continuation to our earlier intimation dated June 30, 2026, please find enclosed the Notice of the 35th AGM (“Notice”) and Annual Report of the Mankind Pharma Limited (“Company”) for the financial year 2025-26 (“Annual Report”). The 35th AGM of the members of the Company is scheduled to be held on Tuesday, August 4, 2026 at 03:30 P.M. (IST) through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”). The Notice and the Annual Report are being sent by e-mail to all the members, whose e-mail address is registered with the Company / Registrar and Share Transfer Agent / Depositories. The Notice and the Annual Report are also available on the Company's website at: Notice https://www.mankindpharma.com/wp-content/uploads/2026/07/Mankind- AGM-Notice-2026_Final.pdf Annual Report https://www.mankindpharma.com/wp-content/uploads/2026/07/Mankind- AR-2025-26_Final.pdf Further, pursuant to Regulation 36(1)(b) of the Listing Regulations, specimen of the letter providing the web-link of the Annual Report, being sent to those members who have not registered their e-mail address, is also attached. The Company will provide the e-voting facility to its members to exercise their right to vote on the resolutions proposed to be passed at the 35th AGM. The cut-off date for determining the members eligible to vote on the resolutions set out in the Notice is Wednesday, July 29, 2026. The remote e-voting facility will be available during the following period: Commencement of remote e-voting Saturday, August 1, 2026 at 9:00 A.M. (IST) End of remote e-voting Monday August, 3, 2026 at 5.00 P.M. (IST) The e-voting facility will also be available during the 35th AGM. Members attending the 35th AGM through VC / OAVM facility who could not cast their vote by remote e-voting will be able to vote during the 35th AGM. A detailed procedure for remote e-voting before and during the 35th AGM has been provided in the Notice. You are requested to kindly take the above information on records. For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer Encl.: A/a Notice 01-14 MANKIND PHARMA LIMITED CIN: L74899DL1991PLC044843 Registered Office: 208, Okhla Industrial Estate, Phase III, New Delhi 110020, Delhi, India. Telephone No. +91(11) 4747 6600 Corporate Office: 262, Okhla Industrial Estate, Phase III, New Delhi 110020, Delhi, India. Telephone No. +91(11) 4684 6700 Website: www.mankindpharma.com | E-mail: investors@mankindpharma.com NOTICE OF 35TH ANNUAL GENERAL MEETING Notice is hereby given that the 35th (Thirty Fifth) Annual (including any statutory modification(s) or re- General Meeting (“AGM”) of the Members of Mankind enactment(s) thereof, for the time being in force) and Pharma Limited will be held on Tuesday, August 04, 2026 the Articles of Association of the Company, approval at 3:30 P.M. (IST) through Video Conferencing (“VC”)/ of the Members be and is hereby accorded to re- Other Audio Visual Means (“OAVM”) to transact the appoint Mr. Satish Kumar Sharma (DIN: 07615602) following businesses: - as Whole Time Director of the Company for a further period of up to 5 (Five) consecutive years with effect ORDINARY BUSINESS from September 22, 2026, liable to retire by rotation, 1. To receive, consider and adopt: - on such terms and conditions of appointment including remuneration as set out in the explanatory a. t he Standalone Audited Financial Statements statement annexed to this Notice. for the Financial Year ended March 31, 2026 and the Report of the Board of Directors and R ESOLVED FURTHER THAT the Board of Directors Auditors thereon. of the Company (‘the Board’) be and is hereby authorized from time to time, to alter, modify, or vary b. the Consolidated Audited Financial Statements the terms and conditions of appointment, including for the Financial Year ended March 31, 2026 and increasing, altering, revising remuneration payable the Report of the Auditors thereon. to Mr. Satish Kumar Sharma (DIN: 07615602) as per, provisions of the Act. 2. To appoint a Director in place of Mr. Rajeev Juneja (DIN: 00283481), who retires by rotation and being RESOLVED FURTHER THAT the Board be and is eligible, offers himself for re-appointment. hereby authorized to do all such acts, deeds and things and to sign all such documents and writings SPECIAL BUSINESS as may be necessary to give effect to this resolution 3. To consider and if thought fit, to pass, the following and for matters connected therewith or incidental resolution as an Ordinary Resolution: - thereto.” APPROVAL FOR RE-APPOINTMENT OF MR. 4. To consider and if thought fit, to pass, the following SATISH KUMAR SHARMA (DIN: 07615602) AS resolution as an Ordinary Resolution: - WHOLE TIME DIRECTOR OF THE COMPANY RATIFICATION OF THE REMUNERATION OF COST “RESOLVED THAT pursuant to the provisions of AUDITORS FOR THE FINANCIAL YEAR 2026-27 Sections 196, 197, 198 and 203 read with Schedule V and other applicable provisions, if any, of the “RESOLVED THAT pursuant to Section 148 and Companies Act, 2013 (‘the Act’) read with the other applicable provisions, if any, of the Companies Companies (Appointment and Remuneration of Act, 2013 read with the Companies (Audit and Managerial Personnel) Rules, 2014, and the Securities Auditors) Rules, 2014 (including any statutory and Exchange Board of India (Listing Obligations amendment(s), modification(s) or re-enactment(s) and Disclosure Requirements) Regulations, 2015 thereof, for the time being in force), the remuneration 35th Annual General Meeting 2025-26 01 Mankind Pharma Limited of ₹ 25,50,000/- (Rupees Twenty Five Lakh Fifty Thousand only) plus applicable taxes as approved by the Board of Directors (“Board”) on the recommendation of the Audit Committee, to be paid to M/s M. K. Kulshrestha & Associates, Cost Accountants, for conducting the cost audit for the financial year 2026-27 be and is hereby ratified. R ESOLVED FURTHER THAT the Board be and is hereby authorized to do all such acts, deeds, things and to sign all such documents and writings as may be necessary to give effect to this resolution and for matters connected therewith or incidental thereto.” By order of the Board of Directors For Mankind Pharma Limited Sd/- Hitesh Kumar Jain Company Secretary & Compliance Officer M. No. F6241 Date: May 19, 2026 Place: New Delhi Regd. Office: 208, Okhla Industrial Estate Phase – III, New Delhi 110020 02 35th Annual General Meeting 2025-26 Notice 01-14 NOTES: - and vote on resolutions proposed at the AGM. Any 1. The Ministry of Corporate Affairs (“MCA”) has vide person who is not a Member as on the Cut-off date its General Circular No. 14/2020 dated April 8, 2020, shall treat this Notice for information purpose only. Circular No. 17/2020 dated April 13, 2020, Circular 5. In terms of Section 152 of the Act, Mr. Rajeev Juneja no. 20/2020 dated May 5, 2020, Circular no. 02/2021 (DIN: 00283481), retires by rotation at the AGM dated January 13, 2021, Circular no. 19/2021 dated and being eligible, offer himself for re-appointment. December 8, 2021, Circular no. 21/2021 dated The Nomination and Remuneration Committee December 14, 2021, Circular no. 2/2022 dated May 5, and the Board of Directors of the Company have 2022, Circular no. 10/2022 dated December 28, 2022, Circular no. 09/2023 dated September 25, 2023, recommended his re-appointment. Circular no. 09/2024 dated September 19, 2024 and 6. The Register of Directors and Key Managerial Circul [Showing first 8,000 characters — download PDF for full document]